JP2014519806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519806A5 JP2014519806A5 JP2014506610A JP2014506610A JP2014519806A5 JP 2014519806 A5 JP2014519806 A5 JP 2014519806A5 JP 2014506610 A JP2014506610 A JP 2014506610A JP 2014506610 A JP2014506610 A JP 2014506610A JP 2014519806 A5 JP2014519806 A5 JP 2014519806A5
- Authority
- JP
- Japan
- Prior art keywords
- strand
- target
- mirna
- strands
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477291P | 2011-04-20 | 2011-04-20 | |
| US201161477283P | 2011-04-20 | 2011-04-20 | |
| US61/477,283 | 2011-04-20 | ||
| US61/477,291 | 2011-04-20 | ||
| US201161477875P | 2011-04-21 | 2011-04-21 | |
| US61/477,875 | 2011-04-21 | ||
| PCT/US2012/034595 WO2012145729A2 (en) | 2011-04-20 | 2012-04-20 | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014519806A JP2014519806A (ja) | 2014-08-21 |
| JP2014519806A5 true JP2014519806A5 (https=) | 2015-07-30 |
Family
ID=47042197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506610A Pending JP2014519806A (ja) | 2011-04-20 | 2012-04-20 | 細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150038549A1 (https=) |
| EP (1) | EP2699271A4 (https=) |
| JP (1) | JP2014519806A (https=) |
| CN (1) | CN104271740A (https=) |
| AU (1) | AU2012245188A1 (https=) |
| BR (1) | BR112013027070A2 (https=) |
| CA (1) | CA2871089A1 (https=) |
| IL (1) | IL228951A0 (https=) |
| RU (1) | RU2013151301A (https=) |
| WO (1) | WO2012145729A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970972B1 (en) * | 2013-03-11 | 2018-08-15 | Fondazione Telethon | Mir-204 and mir-211 and uses thereof |
| BR112015023275B1 (pt) * | 2013-03-15 | 2022-06-21 | Board Of Regents, The University Of Texas System | Método in vitro de detecção de biomarcador de câncer |
| US10119136B2 (en) * | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| US20170051286A1 (en) * | 2014-05-01 | 2017-02-23 | Larry J. Smith | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| US10111898B2 (en) * | 2014-08-27 | 2018-10-30 | Peptimed, Inc. | Anti-tumor compositions and methods |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| CA2997955A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| WO2021108702A1 (en) * | 2019-11-26 | 2021-06-03 | City Of Hope | Microrna as a therapeutic agent |
| US20250297258A1 (en) * | 2021-07-07 | 2025-09-25 | Ractigen Therapeutics | Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof |
| WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
| EP4619524A1 (en) | 2022-11-18 | 2025-09-24 | Genkardia Inc. | Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050119212A1 (en) | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| ATE556714T1 (de) | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| WO2003099840A1 (en) * | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
| WO2005042719A2 (en) | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
| WO2005074966A1 (en) | 2004-02-06 | 2005-08-18 | Adelaide Research & Innovation Pty. Ltd. | A method of modulating cellular uptake and molecules useful for same |
| US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
| US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
| ES2401114T3 (es) | 2004-08-10 | 2013-04-17 | Genzyme Corporation | Modulación antisentido de la expresión de apolipoproteína B |
| EP2377873B1 (en) | 2004-09-24 | 2014-08-20 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| CA2587411A1 (en) | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| US20080249174A1 (en) | 2005-09-07 | 2008-10-09 | The Research Foundation Of State University Of New York | Animal Model for Studying Atherosclerotic Lesions |
| US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| WO2008033285A2 (en) | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
| CA2682082A1 (en) | 2007-03-24 | 2008-10-02 | Genzyme Corporation | Administering antisense oligonucleotides complementary to human apolipoprotein b |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| WO2010105096A2 (en) * | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
| AU2010306940A1 (en) * | 2009-10-12 | 2012-06-07 | Smith, Larry | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
-
2012
- 2012-04-20 CA CA2871089A patent/CA2871089A1/en not_active Abandoned
- 2012-04-20 WO PCT/US2012/034595 patent/WO2012145729A2/en not_active Ceased
- 2012-04-20 JP JP2014506610A patent/JP2014519806A/ja active Pending
- 2012-04-20 CN CN201280029769.5A patent/CN104271740A/zh active Pending
- 2012-04-20 EP EP12774523.0A patent/EP2699271A4/en not_active Withdrawn
- 2012-04-20 RU RU2013151301/10A patent/RU2013151301A/ru not_active Application Discontinuation
- 2012-04-20 US US14/113,093 patent/US20150038549A1/en not_active Abandoned
- 2012-04-20 AU AU2012245188A patent/AU2012245188A1/en not_active Abandoned
- 2012-04-20 BR BR112013027070A patent/BR112013027070A2/pt not_active IP Right Cessation
-
2013
- 2013-10-17 IL IL228951A patent/IL228951A0/en unknown
-
2016
- 2016-04-07 US US15/093,711 patent/US20160272972A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230220393A1 (en) | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | |
| JP2014519806A5 (https=) | ||
| JP2014519806A (ja) | 細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分 | |
| JP7438103B2 (ja) | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| US10526602B2 (en) | Segmented micro RNA mimetics | |
| US10584335B2 (en) | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | |
| US20150291957A1 (en) | METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY | |
| JP6472087B2 (ja) | 治療用オリゴヌクレオチドを送達するための二本鎖剤 | |
| JP5986596B2 (ja) | 非対称性干渉ｒｎａの組成物およびその使用 | |
| JP5244087B2 (ja) | 低分子内部セグメント化干渉ｒｎａ | |
| US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
| JP2022513111A (ja) | Ａｎｇｐｔｌ８を阻害するための新規のｒｎａ組成物および方法 | |
| Martínez et al. | Short-interference RNAs: becoming medicines | |
| WO2025002247A1 (zh) | 靶向人血管生成素样蛋白3的核酸及其用途 | |
| Pérez et al. | MicroRNA interference | |
| Caroleo et al. | Overview of microrna-based therapeutics | |
| NZ617944B2 (en) | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |